| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:17400581 | IVR | 1 mg/kg/day | - | No significant effects observed | - |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Induce apoptosis of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Induce apoptosis of sertoli cells | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Induce apoptosis of sertoli cells | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Induce apoptosis of leydig cells | Reproductive endocrine-mediated perturbations | |
| PMID:19397962 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| PMID:19429406 | IVR | 3 mg/kg/day | 3 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg/day | 1.5 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg/day | 1.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:24753098 | IVR | 0.1 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Liver hypertrophy | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Inflammatory cholestasis | Hepatic endocrine-mediated perturbations;Immunological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Necrosis of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Thymus atrophy | Immunological endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Atrophy of spleen | Immunological endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Atrophy of adrenal gland | Metabolic endocrine-mediated perturbations | |
| PMID:27152447 | IVTH | 0.0000008 - 0.00005 M | 0.000025 - 0.00005 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.